Atul Ltd

Resolution details

• Purpose: approve Vinayak Deshpande as Independent Director for five-year term.
• Term: Aug 1, 2026 to Jul 31, 2031.
• Nature: Special resolution.
• Voting window: Aug 7–Sep 5, 2026; results within two working days.
• Cut-off date: July 31, 2026; voting rights proportional to shareholding.
• Background: four decades in industrial automation; ex MD/CEO of Tata Honeywell.
• Current role: advisor to Tata Sons.
• Recommendation: NRC and Board recommended appointment.
• Appointment effective date: August 1, 2026.
• Results: to be declared within two working days after voting.
• Governance impact: strengthens board independence.

AGM materials release

• AGM 49th proceedings materials uploaded: Chairman's speech, presentation, and video for AGM held July 31, 2026.

AGM Details

• AGM held on 31 July 2026 at 10:30 AM via video conferencing/AVM.
• Meeting concluded at 11:35 AM.
• Record date for voting: 24 July 2026.

Key Resolutions

• Adoption of standalone and consolidated FS for year ended 31 March 2026 — passed.
• Declaration of dividend on equity shares — passed.
• Reappointment of Vivek Gadre as Director — passed.
• Reappointment of Samveg Lalbhai as MD for five years from Dec 15, 2026 — passed.
• Ratification of remuneration of R Nanabhoy & Co for Cost Audit — passed.

AGM Details

• AGM held July 31, 2026 at 10:30 am via video conferencing.
• Meeting concluded at 11:35 am.

Key resolutions and outcomes

• Adoption of standalone and consolidated financial statements for year ended March 31, 2026 (passed).
• Declaration of dividend on equity shares (passed).
• Reappointment of Vivek Gadre as Director (passed).
• Reappointment of Samveg Lalbhai as Managing Director for five years (passed).
• Ratification of remuneration of R Nanabhoy & Co for Cost Audit (passed).

Director changes

• Vivek Gadre reappointed as Director.
• Samveg Lalbhai reappointed as Managing Director (Dec 15, 2026–Dec 14, 2031).

Auditor approvals

• Cost Audit remuneration ratified.

Financial highlights

• Standalone Q1 FY27 income ₹1,614.91 cr; PAT ₹201.03 cr; EPS ₹68.28 basic.
• Standalone revenue up ~21.8% YoY; PAT up ~105%.
• Consolidated Q1 FY27 income ₹1,881.26 cr; PAT ₹253.93 cr.
• Consolidated revenue up ~27.2% YoY; PAT up ~92%.

Segment performance

• Life Science Chemicals revenue ₹469.23 cr; segment profit ₹92.78 cr.
• Performance & Other Chemicals revenue ₹1,427.44 cr; segment profit ₹239.83 cr.
• Others revenue ₹25.98 cr; segment profit ₹6.77 cr.
• Inter-segment revenue ₹74.70 cr; total consolidated revenue ₹1,847.95 cr.
• Consolidated PBT before tax ₹346.83 cr; finance costs ₹4.02 cr; associate JV ₹2.09 cr.

Governance & oversight

• Vinayak Deshpande appointed Independent Director, effective Aug 1, 2026 for five years.
• Board approved results on July 24, 2026; limited reviews completed.
• Deloitte Haskins & Sells LLP conducted reviews; no modifications.

Senior management changes

• Dr Prabhakar Chebiyyam retired as President, Pharmaceuticals.
• Dhaval Vashi appointed Senior Vice President, Pharmaceuticals; effective July 18, 2026.
• Vinay Desai appointed EVP, Technology and Manufacturing; effective July 18, 2026.
• Dhaval Vashi associated with Atul since December 2022; 22 years in business development; MSc and PhD.
• Vinay Desai associated with Atul since December 2022; 35 years in manufacturing; degree in chemical engineering.

Corrigendum corrections

• Corrected medium-term targets: existing capacities ~₹900 cr in sales.
• Own expansions target: ~₹600 cr of additional sales.
• Existing and new joint ventures target: ~₹300 cr.
• Retail figure removed previously stated as ₹121 cr.
• Integrated annual report updated; audited financial statements unchanged.

Financial performance highlights

• Standalone revenue ₹5,564 cr, up 10% YoY.
• Standalone PBT ₹760 cr, up 22% YoY.
• Standalone PAT ₹595 cr; EPS ₹202.11.
• Consolidated revenue ₹6,274 cr, up 12%.
• Consolidated PBT ₹901 cr, up 30%.
• Consolidated PAT ₹689 cr; EPS ₹230.25.

Growth strategy and expansion

• Company remains debt-free with net cash surplus.
• Growth from existing capacity (₹900 cr) and expansions (₹600 cr).
• Retail strategy aims to surpass current B2B sales.
• Atul-Buckman Specialities JV formed Feb 2026, 50-50.

Joint ventures and subsidiaries

• Rudolf Atul Chemicals Ltd is a 50% joint venture.
• Amal Ltd is 49.86% owned; Atul group maintains control.
• Atul Buckman Specialities JV established Feb 2026 for water treatment chemicals.

Governance and board changes

• Shantanu Khosla appointed Independent Director effective Oct 17, 2025.
• Bharathy Mohanan ceased as Whole-time Director May 25, 2025.
• Samveg Lalbhai to be reappointed as Managing Director from Dec 15, 2026.

CSR and ESG highlights

• CSR spend ₹12.14 cr; 37 projects; 3,26,652 beneficiaries.
• Atul Foundation received ₹13 cr from Atul group and ₹13.14 cr from government/donors.
• Trees planted >1.75 lakh under Sanjeevani and related programs.
• Ankleshwar site: zero liquid discharge; 91% treated wastewater recovered; 37% freshwater reduction.

Dividend and AGM updates

• 49th AGM scheduled for July 31, 2026; e-AGM format.
• Final dividend for 2025-26 proposed at ₹30 per share; approval required.

Risks and outlook

• ERM framework strengthened; key risks include digitalisation, geopolitics, cyber, and regulatory changes.
• Forward-looking statements in Letter to Shareholders may vary with conditions.

Dematerialisation processing and certificate status

• Dematerialisation requests processed and confirmed to depositories.
• Dematerialised securities listed on the exchanges where earlier issued securities are listed.
• Physical certificates were mutilated and cancelled; depository's name substituted as registered owner within prescribed timelines.